275 reports of this reaction
1.9% of all DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE reports
#9 most reported adverse reaction
GLAUCOMA is the #9 most commonly reported adverse reaction for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, manufactured by Thea Pharma Inc.. There are 275 FDA adverse event reports linking DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE to GLAUCOMA. This represents approximately 1.9% of all 14,333 adverse event reports for this drug.
Patients taking DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE who experience glaucoma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GLAUCOMA is a less commonly reported adverse event for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, but still significant enough to appear in the safety profile.
In addition to glaucoma, the following adverse reactions have been reported for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE:
The following drugs have also been linked to glaucoma in FDA adverse event reports:
GLAUCOMA has been reported as an adverse event in 275 FDA reports for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
GLAUCOMA accounts for approximately 1.9% of all adverse event reports for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, making it a notable side effect.
If you experience glaucoma while taking DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.